AR
NKTR icon

Advisory Research’s Nektar Therapeutics NKTR Stock Holding History

Advisory Research’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,669
Closed -$2.66M – 384
2018
Q1 		$2.66M Sell
1,669
-765
-31% -$986K 0.05% 188
2017
Q4 		$2.18M Sell
2,434
-665
-21% -$393K 0.04% 213
2017
Q3 		$1.12M Sell
3,099
-604
-16% -$189K 0.02% 291
2017
Q2 		$1.09M Sell
3,703
-3,085
-45% -$892K 0.02% 310
2017
Q1 		$2.39M Sell
6,788
-1,126
-14% -$253K 0.04% 230
2016
Q4 		$1.46M Buy
+7,914
New +$1.61M 0.02% 240

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Advisory Research's NKTR Position: Q2 2018 in Review

Advisory Research sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 1,669 shares — an estimated $2.66M sold.

Advisory Research first reported a position in NKTR in Q4 2016 and held it in 6 quarters. The position peaked at $2.66M in Q1 2018. 378 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • Advisory Research reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Advisory Research sold 1,669 Nektar Therapeutics shares in Q2 2018, an estimated $2.66M.
  • Advisory Research first reported a position in Nektar Therapeutics in Q4 2016 and held it in 6 quarters.
  • Advisory Research's Nektar Therapeutics position peaked at $2.66M in Q1 2018.
  • 378 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Advisory Research's 13F filing for Q2 2018, filed 14 Aug 2018.